391 related articles for article (PubMed ID: 26773297)
1. Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Tilg H; Moschen AR; Szabo G
Hepatology; 2016 Sep; 64(3):955-65. PubMed ID: 26773297
[TBL] [Abstract][Full Text] [Related]
2. Role of the Inflammasome in Liver Disease.
de Carvalho Ribeiro M; Szabo G
Annu Rev Pathol; 2022 Jan; 17():345-365. PubMed ID: 34752711
[TBL] [Abstract][Full Text] [Related]
3. NLRP3 inflammasome in hepatic diseases: A pharmacological target.
Ramos-Tovar E; Muriel P
Biochem Pharmacol; 2023 Nov; 217():115861. PubMed ID: 37863329
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of a Potent and Novel Inhibitor of the NOD-Like Receptor Pyrin Domain-Containing Protein 3 (NLRP3) Inflammasome that Attenuates Development of Nonalcoholic Steatohepatitis and Liver Fibrosis.
Povero D; Lazic M; McBride C; Ambrus-Aikelin G; Stansfield R; Johnson CD; Santini AM; Pranadinata RF; McGeough MD; Stafford JA; Hoffman HM; Feldstein AE; Veal JM; Bain G
J Pharmacol Exp Ther; 2023 Aug; 386(2):242-258. PubMed ID: 37308266
[TBL] [Abstract][Full Text] [Related]
5. Cardiolipin inhibitor ameliorates the non-alcoholic steatohepatitis through suppressing NLRP3 inflammasome activation.
Liu J; Wang T; He K; Xu M; Gong JP
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):8158-8167. PubMed ID: 31599445
[TBL] [Abstract][Full Text] [Related]
6. Bax inhibitor-1 protects from nonalcoholic steatohepatitis by limiting inositol-requiring enzyme 1 alpha signaling in mice.
Lebeaupin C; Vallée D; Rousseau D; Patouraux S; Bonnafous S; Adam G; Luciano F; Luci C; Anty R; Iannelli A; Marchetti S; Kroemer G; Lacas-Gervais S; Tran A; Gual P; Bailly-Maitre B
Hepatology; 2018 Aug; 68(2):515-532. PubMed ID: 29457838
[TBL] [Abstract][Full Text] [Related]
7. IL-1 Family Cytokine Pathways Underlying NAFLD: Towards New Treatment Strategies.
Mirea AM; Tack CJ; Chavakis T; Joosten LAB; Toonen EJM
Trends Mol Med; 2018 May; 24(5):458-471. PubMed ID: 29665983
[TBL] [Abstract][Full Text] [Related]
8. The NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis.
Knorr J; Wree A; Tacke F; Feldstein AE
Semin Liver Dis; 2020 Aug; 40(3):298-306. PubMed ID: 32526788
[TBL] [Abstract][Full Text] [Related]
9. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice.
Petrasek J; Bala S; Csak T; Lippai D; Kodys K; Menashy V; Barrieau M; Min SY; Kurt-Jones EA; Szabo G
J Clin Invest; 2012 Oct; 122(10):3476-89. PubMed ID: 22945633
[TBL] [Abstract][Full Text] [Related]
10. Mitochondria and the NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis.
Torres S; Segalés P; García-Ruiz C; Fernández-Checa JC
Cells; 2022 Apr; 11(9):. PubMed ID: 35563780
[TBL] [Abstract][Full Text] [Related]
11. Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis.
Gaul S; Leszczynska A; Alegre F; Kaufmann B; Johnson CD; Adams LA; Wree A; Damm G; Seehofer D; Calvente CJ; Povero D; Kisseleva T; Eguchi A; McGeough MD; Hoffman HM; Pelegrin P; Laufs U; Feldstein AE
J Hepatol; 2021 Jan; 74(1):156-167. PubMed ID: 32763266
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease.
Lee HJ; Yeon JE; Ko EJ; Yoon EL; Suh SJ; Kang K; Kim HR; Kang SH; Yoo YJ; Je J; Lee BJ; Kim JH; Seo YS; Yim HJ; Byun KS
World J Gastroenterol; 2015 Dec; 21(45):12787-99. PubMed ID: 26668503
[TBL] [Abstract][Full Text] [Related]
13. Cell-specific Deletion of NLRP3 Inflammasome Identifies Myeloid Cells as Key Drivers of Liver Inflammation and Fibrosis in Murine Steatohepatitis.
Kaufmann B; Kui L; Reca A; Leszczynska A; Kim AD; Booshehri LM; Wree A; Friess H; Hartmann D; Broderick L; Hoffman HM; Feldstein AE
Cell Mol Gastroenterol Hepatol; 2022; 14(4):751-767. PubMed ID: 35787975
[TBL] [Abstract][Full Text] [Related]
14. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells.
Csak T; Ganz M; Pespisa J; Kodys K; Dolganiuc A; Szabo G
Hepatology; 2011 Jul; 54(1):133-44. PubMed ID: 21488066
[TBL] [Abstract][Full Text] [Related]
15. Progress in inflammasome activation and pyrolysis in alcoholic liver disease.
Wang S; Qing D
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 Aug; 45(8):999-1004. PubMed ID: 33053545
[TBL] [Abstract][Full Text] [Related]
16. NLRP3 inflammasome activation is required for fibrosis development in NAFLD.
Wree A; McGeough MD; Peña CA; Schlattjan M; Li H; Inzaugarat ME; Messer K; Canbay A; Hoffman HM; Feldstein AE
J Mol Med (Berl); 2014 Oct; 92(10):1069-82. PubMed ID: 24861026
[TBL] [Abstract][Full Text] [Related]
17. Invariant NKT cells promote alcohol-induced steatohepatitis through interleukin-1β in mice.
Cui K; Yan G; Xu C; Chen Y; Wang J; Zhou R; Bai L; Lian Z; Wei H; Sun R; Tian Z
J Hepatol; 2015 Jun; 62(6):1311-8. PubMed ID: 25582105
[TBL] [Abstract][Full Text] [Related]
18. Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH.
Wan X; Xu C; Yu C; Li Y
Can J Gastroenterol Hepatol; 2016; 2016():6489012. PubMed ID: 27446858
[TBL] [Abstract][Full Text] [Related]
19. The P2X7R-NLRP3 and AIM2 Inflammasome Platforms Mark the Complexity/Severity of Viral or Metabolic Liver Damage.
Rossi C; Salvati A; Distaso M; Campani D; Raggi F; Biancalana E; Tricò D; Brunetto MR; Solini A
Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806450
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of NLRP3 inflammasome by thioredoxin-interacting protein in mouse Kupffer cells as a regulatory mechanism for non-alcoholic fatty liver disease development.
He K; Zhu X; Liu Y; Miao C; Wang T; Li P; Zhao L; Chen Y; Gong J; Cai C; Li J; Li S; Ruan XZ; Gong J
Oncotarget; 2017 Jun; 8(23):37657-37672. PubMed ID: 28499273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
